在使用表型个性化药物的肝移植接受者中服用塔克罗利斯的剂量:一项2期随机临床试验
Jeffrey Khong1, Megan Lee2, Curtis Warren3
1Department of Psychology, University of California, Los Angeles, CA, USA.
Nature communications
|May 16, 2025
概括
表型个性化医学 (PPM) 引导剂量改善了肝移植患者的塔克罗利斯药物水平. 这种方法比标准治疗更有效地保持药物值在目标范围内,减少偏差而不会增加不良事件.
科学领域:
- 药理学 药理学是指药理学的学科.
- 移植医学 移植医学
- 个性化医疗是个性化的医疗.
背景情况:
- 塔克罗利马斯是实体器官移植后的重要免疫抑制剂.
- 个体间的变化使得塔克罗利莫斯的剂量复杂化,往往导致血中水平低于最佳水平.
- 保持塔克罗利斯在治疗范围内对于移植成功至关重要.
研究的目的:
- 评估是否一种表型个性化医学 (PPM) 方法改善了肝移植后的塔克罗利斯低谷水平维护.
- 为了比较PPM指导剂量与肝移植接受者的标准护理 (SOC).
主要方法:
- 一个单中心,部分失明的临床试验将62名成年肝移植患者随机分为SOC或PPM引导的塔克罗利斯剂量组.
- 测量的主要结局是移植后几天的百分比与目标塔克罗利木斯范围的显著偏差 (>2 ng/mL).
- 塔克罗利斯的剂量由SOC组的临床医生确定,并在干预组的PPM指导下进行.
主要成果:
- 与SOC组 (n=29) (38.4%) 相比,PPM组 (n=27) 显示出较大的塔克罗利斯偏差 (24.2%) 的日数在统计学上显著减少.
- 大偏差的差异为-14.2% (95% CI: -26.7 至 -1.5%, P=0.029).
- 在PPM和SOC组之间没有观察到不良事件的增加.
结论:
- 以表型个性化医学 (PPM) 为指导的塔克罗利斯剂量在肝移植后维持治疗药物水平方面比标准护理更有效.
- PPM提供了一种有前途的策略,以优化免疫抑制并改善患者在固体器官移植中的结果.
- 这种方法可以提高药物水平的控制,而不会影响患者的安全.
更多相关视频
相关概念视频
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...